Find Encorafenib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

FINISHED DOSAGE FORMULATIONS

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Lgx818, 1269440-17-6, Lgx-818, Braftovi, Encorafenib (lgx818), Nvp-lgx818-nxa
Molecular Formula
C22H27ClFN7O4S
Molecular Weight
540.0  g/mol
InChI Key
CMJCXYNUCSMDBY-ZDUSSCGKSA-N
FDA UNII
8L7891MRB6

Encorafenib
Encorafenib is an orally available Raf kinase inhibitor with potential antineoplastic activity. Encorafenib specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.
1 2D Structure

Encorafenib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
2.1.2 InChI
InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1
2.1.3 InChI Key
CMJCXYNUCSMDBY-ZDUSSCGKSA-N
2.1.4 Canonical SMILES
CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC
2.1.5 Isomeric SMILES
C[C@@H](CNC1=NC=CC(=N1)C2=CN(N=C2C3=C(C(=CC(=C3)Cl)NS(=O)(=O)C)F)C(C)C)NC(=O)OC
2.2 Other Identifiers
2.2.1 UNII
8L7891MRB6
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Braftovi

2. Lgx818

2.3.2 Depositor-Supplied Synonyms

1. Lgx818

2. 1269440-17-6

3. Lgx-818

4. Braftovi

5. Encorafenib (lgx818)

6. Nvp-lgx818-nxa

7. Nvp-lgx-818-nxa

8. Nvp-lgx818

9. 8l7891mrb6

10. Methyl N-[(2s)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate

11. Carbamic Acid, N-[(1s)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1h-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, Methyl Ester

12. Encorafenib [usan:inn]

13. Unii-8l7891mrb6

14. Lgx 818

15. Braftovi (tn)

16. Carbamic Acid, N-((1s)-2-((4-(3-(5-chloro-2-fluoro-3-((methylsulfonyl)amino)phenyl)-1-(1-methylethyl)-1h-pyrazol-4-yl)-2-pyrimidinyl)amino)-1-methylethyl)-, Methyl Ester

17. Encorafenib [mi]

18. Encorafenib(lgx-818)

19. Lgx-818(encorafenib)

20. Encorafenib [inn]

21. Encorafenib [jan]

22. Encorafenib [usan]

23. Encorafenib [who-dd]

24. Encorafenib (jan/usan/inn)

25. Gtpl7908

26. Schembl8228295

27. Chembl3301612

28. Dtxsid00155347

29. Encorafenib [orange Book]

30. Bdbm221688

31. Bcp08458

32. Ex-a1587

33. Mfcd25976758

34. Nsc778304

35. Nsc800093

36. S7108

37. Zinc68249103

38. Ccg-269960

39. Db11718

40. Nsc-778304

41. Nsc-800093

42. Ncgc00378599-03

43. Ac-30230

44. As-35201

45. Hy-15605

46. A13226

47. D11053

48. Us9314464, 9

49. Q15409405

50. (s)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1h-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate

51. Methyl N-((2s)-1-((4-(3-(5-chloro-2-fluoro-3-(methanesulfonamido)phenyl)(-1-(propan-2-yl)-1h-pyrazol-4-yl(pyrimidin-2-yl)amino)propan-2-yl)carbamate

52. Methyl N-[(2s)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1h-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate

2.4 Create Date
2011-03-21
3 Chemical and Physical Properties
Molecular Weight 540.0 g/mol
Molecular Formula C22H27ClFN7O4S
XLogP32.7
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count10
Rotatable Bond Count10
Exact Mass539.1517794 g/mol
Monoisotopic Mass539.1517794 g/mol
Topological Polar Surface Area149 Ų
Heavy Atom Count36
Formal Charge0
Complexity836
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Used in combination with [Binimetinib] in metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.


Encorafenib is indicated:

- in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation

- in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy


Treatment of colorectal carcinoma


Treatment of melanoma


5 Pharmacology and Biochemistry
5.1 Pharmacology

Encorafenib has shown improved efficacy in the treatment of metastatic melanoma. Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis. Once-daily dosing of single-agent encorafenib has a distinct tolerability profile and shows varying antitumor activity across BRAFi-pretreated and BRAFi-nave patients with advanced/metastatic stage melanoma.


5.2 ATC Code

L01EC03


L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01E - Protein kinase inhibitors

L01EC - B-raf serine-threonine kinase (braf) inhibitors

L01EC03 - Encorafenib


5.3 Absorption, Distribution and Excretion

Absorption

After oral administration, the median Tmax of encorafenib is 2 hours. At least 86% of the dose is absorbed. Administration of a single dose of BRAFTOVI 100 mg (0.2 times the recommended dose) with a high-fat, high-calorie meal (comprised of approximately 150 calories from protein, 350 calories from carbohydrates, and 500 calories from fat) decreased the mean maximum encorafenib concentration (Cmax) by 36% with no effect on AUC (area under the curve).


Route of Elimination

Following a single oral dose of 100 mg radiolabeled encorafenib, 47% (5% unchanged) of the administered dose was recovered in the feces and 47% (2% unchanged) was recovered in the urine.


Volume of Distribution

The blood-to-plasma concentration ratio is 0.58. The geometric mean (CV%) of apparent volume of distribution is 164 L (70%).


Clearance

The apparent clearance is 14 L/h (54%) at day 1, increasing to 32 L/h (59%) at steady-state.


5.4 Metabolism/Metabolites

The primary metabolic pathway is N-dealkylation, with CYP3A4 as the main contributor (83%) to total oxidative clearance of encorafenib in human liver microsomes, followed by CYP2C19 (16%) and CYP2D6 (1%).


5.5 Biological Half-Life

The mean (CV%) terminal half-life (t1/2) of encorafenib is 3.5 hours (17%)


5.6 Mechanism of Action

Encorafenib is a kinase inhibitor that specifically targets BRAF V600E, as well as wild-type BRAF and CRAF while tested with in vitro cell-free assays with IC50 values of 0.35, 0.47, and 0.3 nM, respectively. Mutations in the BRAF gene, including BRAF V600E, result in activated BRAF kinases that mahy stimulate tumor cell growth. Encorafenib is able to bind to other kinases in vitro including JNK1, JNK2, JNK3, LIMK1, LIMK2, MEK4, and STK36 and significantly reduce ligand binding to these kinases at clinically achievable concentrations ( 0.9 M). In efficacy studies, encorafenib inhibited the in vitro cell growth of tumor cell lines that express BRAF V600 E, D, and K mutations. In mice implanted with tumor cells expressing the BRAF V600E mutation, encorafenib induced tumor regressions associated with RAF/MEK/ERK pathway suppression. Encorafenib and binimetinib target two different kinases in the RAS/RAF/MEK/ERK pathway. Compared with either drug alone, co-administration of encorafenib and binimetinib result in greater anti-proliferative activity in vitro in BRAF mutation-positive cell lines and greater anti-tumor activity with respect to tumor growth inhibition in BRAF V600E mutant human melanoma xenograft studies in mice. In addition to the above, the combination of encorafenib and binimetinib acted to delay the emergence of resistance in BRAF V600E mutant human melanoma xenografts in mice compared with the administration of either drug alone.


NDC API

read-more
read-more

01

Finorga

Germany
arrow
BIO Partnering at JPM
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAxplora- The partner of choice for complex APIs.

Flag Germany
Digital Content Digital Content

ENCORAFENIB

NDC Package Code : 62009-1913

Start Marketing Date : 2018-09-28

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Axplora CB

02

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

ENCORAFENIB

NDC Package Code : 59651-641

Start Marketing Date : 2023-12-18

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (50kg/50kg)

Marketing Category : BULK INGREDIENT

blank

03

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

ENCORAFENIB

NDC Package Code : 54893-0114

Start Marketing Date : 2021-03-30

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"ENCORAFENIB","year":"2021","qtr":"Q1","strtotime":1612981800,"product":"ENCORAFENIB (GROUP:A) (TAX INV NO:190520 5269 DT:04.02.2021","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"MIAMI FL","customer":"ACTAVIS INC","customerCountry":"UNITED STATES","quantity":"0.43","actualQuantity":"430","unit":"GMS","unitRateFc":"249.3","totalValueFC":"106082.2","currency":"USD","unitRateINR":17961.623255813953,"date":"11-Feb-2021","totalValueINR":"7723498","totalValueInUsd":"106082.2","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"8560335","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1629138600,"product":"ENCORAFENIB (TAX INV NO:1905215171 DT:13 .08.2021)","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"LJUBLJANA - BRNIK","customer":"SANDOZ B2B","customerCountry":"SLOVENIA","quantity":"2.80","actualQuantity":"2.8","unit":"KGS","unitRateFc":"50696.1","totalValueFC":"137896.4","currency":"USD","unitRateINR":3652652.8571428573,"date":"17-Aug-2021","totalValueINR":"10227428","totalValueInUsd":"137896.4","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"3898714","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1728930600,"product":"ENCORAFENIB","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"DEVA HOLDING A.S-CERKEZKOY 2","customerCountry":"TURKEY","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"30000","totalValueFC":"8807.2","currency":"USD","unitRateINR":2466783.3333333335,"date":"15-Oct-2024","totalValueINR":"740035","totalValueInUsd":"8807.2","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"4830681","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""}]
11-Feb-2021
15-Oct-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Encorafenib Manufacturers

A Encorafenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Encorafenib, including repackagers and relabelers. The FDA regulates Encorafenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Encorafenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Encorafenib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Encorafenib Suppliers

A Encorafenib supplier is an individual or a company that provides Encorafenib active pharmaceutical ingredient (API) or Encorafenib finished formulations upon request. The Encorafenib suppliers may include Encorafenib API manufacturers, exporters, distributors and traders.

click here to find a list of Encorafenib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Encorafenib USDMF

A Encorafenib DMF (Drug Master File) is a document detailing the whole manufacturing process of Encorafenib active pharmaceutical ingredient (API) in detail. Different forms of Encorafenib DMFs exist exist since differing nations have different regulations, such as Encorafenib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Encorafenib DMF submitted to regulatory agencies in the US is known as a USDMF. Encorafenib USDMF includes data on Encorafenib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Encorafenib USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Encorafenib suppliers with USDMF on PharmaCompass.

Encorafenib WC

A Encorafenib written confirmation (Encorafenib WC) is an official document issued by a regulatory agency to a Encorafenib manufacturer, verifying that the manufacturing facility of a Encorafenib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Encorafenib APIs or Encorafenib finished pharmaceutical products to another nation, regulatory agencies frequently require a Encorafenib WC (written confirmation) as part of the regulatory process.

click here to find a list of Encorafenib suppliers with Written Confirmation (WC) on PharmaCompass.

Encorafenib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Encorafenib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Encorafenib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Encorafenib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Encorafenib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Encorafenib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Encorafenib suppliers with NDC on PharmaCompass.

Encorafenib GMP

Encorafenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Encorafenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Encorafenib GMP manufacturer or Encorafenib GMP API supplier for your needs.

Encorafenib CoA

A Encorafenib CoA (Certificate of Analysis) is a formal document that attests to Encorafenib's compliance with Encorafenib specifications and serves as a tool for batch-level quality control.

Encorafenib CoA mostly includes findings from lab analyses of a specific batch. For each Encorafenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Encorafenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Encorafenib EP), Encorafenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Encorafenib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty